Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2019 Earnings Presentation
12 slides from Alkem Laboratories's earnings presentation, Feb 8, 2019
Slide 1: Investor Presentation Q3FY19 – February 8, 2019
Investor Presentation Q3FY19 – February 8, 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q3FY19 and 9MFY19
Key Highlights of Q3FY19 and 9MFY19 • India Business: Company’s India sales registered 0.7% YoY decline in Q3FY19 on account of ban on select FDC products, slower growth in anti-infective and gastro-intestinal market and de-growth in trade generic business due to tightening of credit terms • Company
Slide 4: Key Financial Highlights – Q3FY19 (Consolidated)
Key Financial Highlights – Q3FY19 (Consolidated) All figures in Rs mn Revenue from Operations India sales 12,567 YoY: (0.7)% 12,475 19,250 17,412 Q3FY18 Q3FY19 International sales 6,532 4,659 Q3FY18 Q3FY19 Q3FY18 Q3FY19
Slide 5: Key Financial Highlights – Q3FY19 (Consolidated)
Key Financial Highlights – Q3FY19 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin YoY: (1.1)% 11,148 11,020 3,605 3,118 64.0% 57.2% 20.7% 16.2% Q3FY18 Q3FY19 Q3FY18 Q3FY19 PBT (before Minority Interest) PAT (after Minority Interest) 3,324 2,025 2,581 1,716
Slide 6: India Business
India Business India Business: Q3FY19 Sales of Rs.12,475 million (0.7% YoY decline) • YoY decline in India sales during Q3FY19 was mainly on account of ban on select FDC products, de-growth in Company’s trade generic business due to tightening of credit terms, slower growth in the anti-infective mar
Slide 7: India Business – Secondary Sales Performance
India Business – Secondary Sales Performance Outperformance across most of the major therapeutic areas in 9MFY19 -1 Established therapeutic Market rank 1 3 3 5 areas of Alkem 17.8% 13.9% 13.8% 13.0% 7.8% 9.0% 9.1% 5.8% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients
Slide 8: US Business
US Business US Business: Q3FY19 Sales of Rs.5,182 million (44.3% growth YoY) • US sales contributed 27.3% to total sales in Q3FY19 • Growth in the US business was driven by combination of new product launches and market share gains in the existing products. Depreciation of INR against USD also helpe
Slide 9: Update on the US FDA inspection
Update on the US FDA inspection In the month of January and February 2019, the US FDA conducted inspections at the Company’s formulation manufacturing facilities located at Daman (India) and St. Louis (US). At the end of the inspection, no Form 483 was issued for the Daman facility, while the St. Lo
Slide 10: Other International Business
Other International Business Other International Business: Q3FY19 Sales of Rs.1,349 million (26.4% YoY growth) • Other International Market sales contributed 7.1% to total sales in Q3FY19 • The Company has presence in Australia, Europe, South East Asia, Latin America, Africa and CIS • Australia and
Slide 11: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on December 31, 2018 Non-Institution, 26.30% Promoter & Institution, Promoter Group, 7.73% 65.98% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other Bo
Slide 12: Thank You
Thank You DP ar @.